Results of Meeting
Released
Released
Announcement PDF
ASX Announcement
25 Jan 2023
Results of General Meeting
Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech, advises that a
General Meeting of shareholders was held today, 25 January 2023. All resolutions put to the
meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of
the Corporations Act, the Company advises that details of the poll results and the proxies
received in respect of each resolution are set out below:
Poll Results
For
Resolutions
Against
Abstain
Number
%
Number
%
Number
1
Ratification of prior issue of
Tattarang Shares under Listing
Rule 7.1A
105,994,009
99.93
78,497
0.07
216,250
2
Ratification of prior issue of
Tattarang Options under
Listing Rule 7.1
106,892,241
99.87
138,497
0.13
156,250
3(a)
Approval of Issue of Tranche 2
Director Securities – Dr
Stewart Washer
59,800,538
99.7
182,343
0.30
21,582,064
3(b)
Approval of Issue of Tranche 2
Director Securities – Dr Karen
Smith
109,126,137
99.83
182,343
0.17
656,465
3(c)
Approval of Issue of Tranche 2
Director Securities – Dr Alistair
Vickery
109,126,137
99.83
182,343
0.17
656,465
3(d)
Approval of Issue of Tranche 2
Director Securities – Mr
Matthew Callahan
89,526,137
99.80
182,343
0.20
20,256,465
3(e)
Approval of Issue of Tranche 2
Director Securities – Dr
Michael Winlo
109,186,137
99.89
122,343
0.11
656,465
4
Approval of issue of Lead
Manager Options
108,960,198
99.88
348,497
0.32
656,250
1
Proxy Votes Received
Resolutions
For
Against
At Proxy
Holders
Discretion
Abstain
1
Ratification of prior issue of
Tattarang Shares under Listing
Rule 7.1A
98,215,450
78,497
51,000
216,250
2
Ratification of prior issue of
Tattarang Options under
Listing Rule 7.1
99,113,862
138,497
51,000
156,250
3(a)
Approval of Issue of Tranche 2
Director Securities – Dr
Stewart Washer
53,357,578
182,343
41,000
20,256,465
3(b)
Approval of Issue of Tranche 2
Director Securities – Dr Karen
Smith
101,357,578
182,343
41,000
656,465
3(c)
Approval of Issue of Tranche 2
Director Securities – Dr Alistair
Vickery
101,357,578
182,343
41,000
656,465
3(d)
Approval of Issue of Tranche 2
Director Securities – Mr
Matthew Callahan
81,757,578
182,343
41,000
20,256,465
3(e)
Approval of Issue of Tranche 2
Director Securities – Dr
Michael Winlo
101,417,578
122,343
41,000
656,465
4
Approval of issue of Lead
Manager Options
101,191,639
348,497
41,000
656,250
Release authorised by:
Simon Robertson
Company Secretary
FOR FURTHER INFORMATION
Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com
Andrew Williams
Media Relations
+61 (0) 416 583 672
awilliams@emyria.com
Sufian Ahmad
Corporate Advisor
+61 (0) 412 316 162
info@62capital.com.au
UPCOMING DRUG DEVELOPMENT MILESTONES
DRUG DEVELOPMENT
NEW DRUG DISCOVERY
CLINICAL PROGRAMS
Ultra-Pure cannabinoid delivery platform
PRE-CLINICAL PROGRAM
MDMA-like analogues
EMD-RX5 “direct-to-consumer”
EMD-RX7 “prescription medicine”
MDMA-like drug development
Formulation optimisation
Formulation optimisation
Continuous creation & screening
Phase 1 study
Phase 1
First patent family filed
Ethics approved for Phase 3
Pre-IND (FDA)
US-focussed preclinical program
Phase 3 commencement
Pivotal trials
Metabolic studies
Regulatory submission
Preclinical assays (multiple animal models)
Commercial strategy Australia
Human cell line assays
Commercial strategy Europe
Advanced assay development
Commercial strategy USA
Lead selection
Phase 1 trials
ABOUT EMYRIA | emyria.com
Global commercial strategy
Emyria Limited is a clinical drug development and care delivery company focused on accelerating
drug development and improving patient outcomes in neuroscience and mental health via:
●
Drug Development: Emyria has developed an Ultra-Pure cannabinoid platform that can
support the registration of multiple proprietary dose forms. Emyria’s first dose form,
EMD-RX5 is in Phase 3 trials
●
New Drug Discovery: Inspired by MDMA, Emyria is developing one of the world’s largest
libraries of MDMA-like compounds with partner, the University of Western Australia.
●
Proprietary Real-World Data (RWD): Emyria gathers ethically-sourced data with patients
cared for at Emyria’s own specialist clinical service (Emerald Clinics).
Emyria RWD can help support drug development and care model improvement.
EMYRIA’S
INTERACTIVE
INVESTOR
HUB
Investorhub.emyria.com Interact with Emyria’s announcements and updates by
asking questions and comments, which our team can respond to where possible.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release
about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and
other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors, including: the Company’s ability to
successfully develop its product candidates and timely complete its planned clinical programs and the
Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking
statements included in this press release represents the Company’s views as of the date hereof. The Company
anticipates that subsequent events and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied
upon as representing the Company’s views as of any date subsequent to the date hereof.
Share your feedback
Discover